What is Manifold Bio?
Manifold Bio is a pioneering biotechnology company dedicated to revolutionizing the drug discovery process through the power of multiplexed measurement. By integrating sophisticated engineering principles with biological research, the firm aims to streamline the development of novel therapeutics. Their platform is designed to address the inherent complexities of biological systems, allowing for more precise and efficient identification of drug candidates. As a deep tech entity, Manifold Bio sits at the intersection of data science and life sciences, creating a scalable infrastructure that supports the rapid iteration and validation of therapeutic interventions. Their market position is defined by a commitment to solving fundamental challenges in medicine, effectively bridging the gap between academic innovation and commercial-scale pharmaceutical development.
How much funding has Manifold Bio raised?
Manifold Bio has raised a total of $45.4M across 2 funding rounds:
Angel/Seed
$5.4M
Series A
$40M
Angel/Seed (2020): $5.4M with participation from GETTYLAB, Playground Global, Allston Venture Fund, and Fifty Years
Series A (2022): $40M led by Section 32, FPV Ventures, Tencent, Fifty Years, Horizons Ventures, Triatomic Capital, and Playground Global
Key Investors in Manifold Bio
Tencent
Tencent is a global technology company that develops digital platforms, software, and internet based services for consumers and businesses, investing in technology innovation across multiple industries.
Fifty Years
Fifty Years is a pre-seed and seed focused venture capital firm that supports founders leveraging technology to address significant global challenges such as climate change, disease, and malnutrition.
Playground Global
Playground Global invests in founders harnessing frontier technologies to build transformational businesses with multi-generational impact, focusing on artificial intelligence, automation, and life sciences.
What's next for Manifold Bio?
With the infusion of this latest capital, Manifold Bio is well-positioned to scale its research and development initiatives. The strategic focus will likely shift toward expanding its proprietary measurement platform and deepening its pipeline of therapeutic candidates. As the company matures, the emphasis will remain on translating complex biological data into actionable insights that can significantly reduce the time and cost associated with bringing new treatments to market. Investors will be closely monitoring the firm's ability to maintain its technological edge while navigating the regulatory and clinical hurdles inherent in the biotech industry. The continued support from its diverse investor base suggests a long-term commitment to building a sustainable, high-impact enterprise capable of transforming the landscape of modern medicine.
See full Manifold Bio company page
